Steve Ferguson (Medix Biochemica Oy)

Ferguson, Steve (Medix Biochemica 202201 CEO)

	Product	in vitro diagnostics (IVD)
	Product 2	antibody, diagnostic

Medix Biochemica Oy. (2/1/22). "Press Release: Medix Biochemica Expands Its Molecular Diagnostics Business through the Acquisition of myPOLS Biotec". Espoo.

> The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics.

> This acquisition enables customers to benefit from even stronger scientific and technological expertise in molecular diagnostics, and further strengthens the company’s global presence.

> The full myPOLS Biotec product portfolio will now be available through Medix Biochemica’s global sales network.

Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of myPOLS Biotec GmbH (“myPOLS Biotec”). As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics (“IVD”) industry, complements its scientific expertise and strengthens its local presence in Western Europe. myPOLS Biotec will form a significant part of the newly established Molecular Diagnostics Business Unit within Medix Biochemica Group, and its high-quality operations will continue in Konstanz, Germany. All founders of myPOLS Biotec will remain involved in the business following the transaction with ongoing commitment to innovation and growth of the molecular diagnostics reagents business together with the site in Konstanz.

“This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry, and it further accelerates Medix Biochemica’s growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of myPOLS Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica’s existing molecular diagnostics offering. With myPOLS technology, we enable customers to shorten their assay development time and complexity, perform molecular testing directly from crude samples and offer more flexibility to assay development by partnering in custom development. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base,” says Steve Ferguson, CEO of Medix Biochemica.

“We are thrilled to join Medix Biochemica Group,” says Dr. Ramon Kranaster, CEO of myPOLS Biotec. “We are looking forward to contributing to the strong growth of Medix Biochemica and we appreciate its clear focus on quality and R&D. The high scientific competence of the myPOLS team including best-in-class DNA polymerases, supports Medix Biochemica’s long term vision and focus on IVD customers’ needs.”

About myPOLS

myPOLS Biotec is an innovative biotechnology company based in Konstanz, Germany, offering best-in-class DNA polymerases, master mixes, DNA polymerase-based assays and reagents in both liquid and lyophilized format for IVD and research use. Founded in 2014, myPOLS Biotec started as a spin-off by scientists from the University of Konstanz, developing high-quality reagents and raw materials for molecular diagnostics by excelling in tailoring DNA polymerases for various applications, such as PCR, CRISPR, NGS and isothermal, and robust SNP detection. Since April 2019, myPOLS Biotec has been certified according to ISO 13485:2016 and its products and services are successfully deployed by leading in vitro diagnostics companies worldwide, as well as laboratories, research organisations, and pharmaceutical companies.

All founders of myPOLS Biotec will remain involved in the business following the acquisition with Dr. Ramon Kranaster and Simone Marx having key operational roles in the Molecular Diagnostics Business Unit and Prof. Dr. Andreas Marx continuing as a Senior Advisor.

About Medix Biochemica

Medix Biochemica Group are a global, market-leading supplier of critical raw materials to the in vitro diagnostics (IVD) industry. Our mission is to enable IVD customers to deliver accurate results to billions of patients worldwide. By working in partnership with Medix Biochemica, IVD manufacturers can reduce their time to market through our industry-leading expertise which increases efficiencies and builds quality into their tests. We achieve this through our deep scientific know-how combined with the broadest and most relevant raw material portfolio and our relentless focus on quality. Medix Biochemica Group employs more than 240 professionals worldwide. With headquarters in Finland, we serve our worldwide customers through our local teams in the US, Europe, and Asia. www.medixbiochemica.com

We Care. We Dare. We Deliver.

More information

Steve Ferguson, CEO of Medix Biochemica
Phone: +358 9 547 680
Email: steve.ferguson@medixbiochemica.com